22 May 2024 - Cartesian Therapeutics today announced that the US FDA has granted regenerative medicine advanced therapy designation for Descartes-08 for the treatment of myasthenia gravis.

Descartes-08, the Company’s lead product candidate, is an autologous mRNA CAR-T directed against the B cell maturation antigen initially being developed for the treatment of myasthenic gravis, a chronic auto-immune disorder that causes disabling muscle weakness and fatigue.

Read Cartesian Therapeutics press release